SCHEMBL4031706

SCHEMBL4031706

Cc1oc(-c2ccccc2)nc1CCc1ccc(CO)cc1

nearest known ligand 0.57

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.57
KDM4E B2RXH2 1/20 0.57
PPARG P37231 13/20 0.56
PPARA Q07869 11/20 0.56
FFAR1 O14842 1/20 0.55
HRH3 Q9Y5N1 1/20 0.54
ALDH1A1 P00352 1/20 0.51
MAPT P10636 1/20 0.51
PPARD Q03181 1/20 0.50
HPGD P15428 1/20 0.50
PDE10A Q9Y233 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6384453 0.92 PPARG (0.66) KDRKDM4EPPARGPPARAFFAR1
SCHEMBL3279259 0.85 PPARG (0.72) PPARGPPARAPPARD
SCHEMBL7486859 0.85 KDM4E (0.57) KDM4EPPARGPPARAFFAR1HRH3
SCHEMBL7486865 0.84 PPARG (0.53) KDRKDM4EPPARGPPARAFFAR1
SCHEMBL7486861 0.84 PPARG (0.53) KDRKDM4EPPARGPPARAFFAR1
SCHEMBL979145 0.83 KDM4E (0.65) KDRKDM4EPPARGPPARAFFAR1
SCHEMBL4037331 0.83 KDM4E (0.69) KDRKDM4EPPARGPPARAFFAR1
SCHEMBL6220972 0.83 KDM4E (0.54) KDM4EPPARGPPARAFFAR1HRH3
SCHEMBL7484969 0.81 PPARG (0.48) KDRKDM4EPPARGPPARAFFAR1
SCHEMBL7484975 0.81 PPARG (0.48) KDRKDM4EPPARGPPARAFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1357115-B1 ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2009-06-17 EP disclosed
US-7238716-B2 Alkanoic acid derivatives process for their production and use thereof TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) 2007-07-03 US disclosed
US-20040058965-A1 Alkanoic acid derivatives process for their production and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-25 US disclosed
EP-1357115-A1 ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-10-29 EP disclosed
EP-0643050-B1 Oxazolidinedione derivatives and their use as hypoglycemic agent TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2002-04-10 EP disclosed
US-5614544-A HYPOGLYCEMIC AND HYPOLIPIDEMIC AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-03-25 US disclosed
EP-0643050-A1 Oxazolidinedione derivatives and their use as hypoglycemic agent Takeda Chemical Industries, Ltd. (JP) 1995-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058965-A1 Alkanoic acid derivatives process for their production and use thereof GPR119, ACOX1, ALK KDR 1328/4885KDM4E 570/4885PPARG 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.